China Shineway Pharmaceutical Group Limited
CSWYF
$0.9398
$0.07378.51%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 525.10M | 554.20M | 582.27M | 609.35M | 639.32M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 525.10M | 554.20M | 582.27M | 609.35M | 639.32M |
| Cost of Revenue | 131.53M | 138.06M | 144.33M | 151.24M | 158.87M |
| Gross Profit | 393.57M | 416.14M | 437.94M | 458.11M | 480.45M |
| SG&A Expenses | 263.47M | 278.14M | 292.26M | 308.97M | 327.12M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 408.97M | 430.62M | 451.41M | 475.38M | 501.56M |
| Operating Income | 116.13M | 123.58M | 130.86M | 133.97M | 137.75M |
| Income Before Tax | 159.09M | 178.77M | 198.24M | 186.62M | 175.64M |
| Income Tax Expenses | 42.44M | 43.87M | 45.25M | 41.81M | 38.55M |
| Earnings from Continuing Operations | 116.65 | 134.91 | 152.99 | 144.80 | 137.09 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 116.65M | 134.91M | 152.99M | 144.80M | 137.09M |
| EBIT | 116.13M | 123.58M | 130.86M | 133.97M | 137.75M |
| EBITDA | 132.41M | 143.46M | 153.08M | 156.76M | 161.22M |
| EPS Basic | 0.15 | 0.18 | 0.20 | 0.19 | 0.18 |
| Normalized Basic EPS | 0.13 | 0.15 | 0.16 | 0.15 | 0.15 |
| EPS Diluted | 0.15 | 0.18 | 0.20 | 0.19 | 0.18 |
| Normalized Diluted EPS | 0.13 | 0.15 | 0.16 | 0.15 | 0.15 |
| Average Basic Shares Outstanding | 3.02B | 3.02B | 3.02B | 3.02B | 3.02B |
| Average Diluted Shares Outstanding | 3.02B | 3.02B | 3.02B | 3.02B | 3.02B |
| Dividend Per Share | 0.07 | 0.07 | 0.07 | 0.07 | 0.06 |
| Payout Ratio | 48.55% | 41.96% | 36.96% | 35.10% | 33.05% |